Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
The company’s lead program Tividenofusp alfa, an enzyme-replacement therapy for Hunter syndrome, shows promise as a best-in-class treatment, the analyst highlights. William Blair has initiated ...
Despite these results, the analyst believes that Denali's core value lies in its Transport Vesicle (TV) platform and the promising prospects of Tividenofusp alfa, which is expected to be submitted for ...
Despite these results, the analyst believes that Denali's core value lies in its Transport Vesicle (TV) platform and the promising prospects of Tividenofusp alfa, which is expected to be submitted ...
The company’s lead program Tividenofusp alfa, an enzyme-replacement therapy for Hunter syndrome, shows promise as a best-in-class treatment, the analyst highlights. William Blair has initiated with an ...
tividenofusp alfa (DNL310). According to InvestingPro data, analyst targets for DNLI range from $24 to $90, with the stock currently trading at $19.82. Denali's DNL310, an enzyme replacement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback